Publications by authors named "Mohammad Parsa-Kondelaji"

The present systematic review aimed to explore miRNAs as a potential biomarker for early diagnosis of chronic myeloid leukemia (CML). A systematic search was conducted in three electronic databases, including Web of Science, Scopus and PubMed, to obtain relevant articles investigating the alteration of miRNA expression in patients with CML. The authors found miRNAs whose expression changes are effective in the induction of CML disease.

View Article and Find Full Text PDF

Objective: Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism. The body's hemostatic system responds differently to these drugs in different people.

View Article and Find Full Text PDF

To evaluate the frequency and prognosis of runt-related transcription factor 1 (RUNX1) and additional sex combs like-1 (ASXL1) mutations in acute myeloid leukaemia (AML) patients in northeastern Iran. This cross-sectional study was performed on 40 patients with AML (including 35 patients with denovo AML and five patients with secondary AML) from February 2018 to February 2021. All patients were followed up for 36 months.

View Article and Find Full Text PDF

Background: Newly discovered evidence showed that long non-coding RNAs (lncRNAs) can play crucial roles in the development of cancer therapies. Nuclear Enriched Abundant Transcripts 1 (NEAT1) is one of the lncRNAs the expression of which changes in different cancers. The role of NEAT1 in apoptosis is discussed in various malignancies.

View Article and Find Full Text PDF

The SARS-CoV-2 virus has spread to all corners of the world. Thrombosis is the cause of organ failure and subsequent death in COVID-19. The pathophysiology of thrombosis in COVID-19 needs to be further explored to shed light on its downside.

View Article and Find Full Text PDF

TGF-β contributes to drug resistance and the invasiveness of tumor cells and weakens the anti-tumor immune responses. The present study aimed at examining the efficacy of the combination of SB431542, as a specific inhibitor of TGF-βR, and doxorubicin in controlling the melanoma tumor in mice. The impact of the combination of the doxorubicin and SB431542 on the cell growth, apoptosis, migration, and invasiveness of B16-F10 cells was examined.

View Article and Find Full Text PDF